Successful treatment of autoimmune lymphoproliferative syndrome and refractory autoimmune thrombocytopenic purpura with a reduced intensity conditioning stem cell transplantation followed by donor lymphocyte infusion [5]

Bone Marrow Transplantation

Volumn 40, Issue 6, 2007, Pages 605-606

  Dimopoulou, M N ^a   Gandhi, S ^a   Ghevaert, C ^b   Chakraverty, R ^a   Fielding, A ^a   Webster, D ^a   Mackinnon, S ^a   Kottaridis, P D ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b Cambridge Blood Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOSPORIN; FIBRINOGEN RECEPTOR; FLUDARABINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; THROMBOCYTE ANTIBODY; VINCRISTINE;

ADULT; ANAMNESIS; ANTIBODY DETECTION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BONE MARROW BIOPSY; CASE REPORT; CHIMERA; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; DONOR SELECTION; GENETIC ANALYSIS; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; LETTER; LYMPHOPROLIFERATIVE DISEASE; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; REDUCED INTENSITY CONDITIONING; RESPIRATORY TRACT INFECTION; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIC PURPURA;

ADULT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; LYMPHOPROLIFERATIVE DISORDERS; MALE; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TRANSPLANTATION CONDITIONING;

EID: 34548532952     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705775     Document Type: Letter

References (9)

1. Worth A, Thrasher AJ, Gaspar HB. Autoimmune lymphoproliferative syndrome: Molecular basis of disease and clinical phenotype. Br J Haematol 2006; 133: 124-140.
2. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: The autoimmune lymphoproliferative syndrome. Ann Intern Med 1999; 130: 591-601.
3. Sneller MC, Wang J, Dale JK, Strober W, Middelton LA, Choi Y et al. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis. Blood 1997; 89: 1341-1348.
4. Rieux-Laucat F, Le Deist F, Fischer A. Autoimmune lymphoproliferative syndromes: Genetic defects of apoptosis pathways. Cell Death Differ 2003; 10: 124-133.
5. Poppema S, Maggio E, van den Berg A. Development of lymphoma in Autoimmune Lymphoproliferative Syndrome (ALPS) and its relationship to Fas gene mutations. Leuk Lymphoma 2004; 45: 423-431.
6. Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfuerth S et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002; 99: 1071-1078.
7. Sleight BJ, Prasad VS, DeLaat C, Steele P, Ballard E, Arceci RJ et al. Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow Transplant 1998; 22: 375-380.
8. Benkerrou M, Le Deist F, de Villartay JP, Caillat-Zucman S, Rieux-Laucat F, Jabado N et al. Correction of Fas (CD95) deficiency by haploidentical bone marrow transplantation. Eur J Immunol 1997; 27: 2043-2047.
9. Vacek MM, Schaffer AA, Davis J, Fischer RE, Dale JK, Adams S et al. HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia). Clin Immunol 2006: 118: 59-65.